about
Aspiration thrombectomy in patients undergoing primary angioplasty: totality of data to 2013.An FFRCT diagnostic strategy versus usual care in patients with suspected coronary artery disease planned for invasive coronary angiography at German sites: one-year results of a subgroup analysis of the PLATFORM (Prospective Longitudinal Trial of FSafety and efficacy of the Yukon Choice Flex sirolimus-eluting coronary stent in an all-comers population cohort.Dual antiplatelet therapy duration after coronary stenting in clinical practice: results of an EAPCI survey.2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS):Percutaneous coronary interventional strategies for treatment of in-stent restenosis: a network meta-analysis.Monocytes, neutrophils, and platelets cooperate to initiate and propagate venous thrombosis in mice in vivo.Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22,844 patient years of follow-up from randomised trials.Histopathological evaluation of thrombus in patients presenting with stent thrombosis. A multicenter European study: a report of the prevention of late stent thrombosis by an interdisciplinary global European effort consortiumThe Extracellular Matrix Metalloproteinase Inducer (EMMPRIN, CD147) - a potential novel target in atherothrombosis prevention?Current treatment of in-stent restenosis.Randomized, non-inferiority trial of three limus agent-eluting stents with different polymer coatings: the Intracoronary Stenting and Angiographic Results: Test Efficacy of 3 Limus-Eluting Stents (ISAR-TEST-4) Trial.A polymer-free dual drug-eluting stent in patients with coronary artery disease: a randomized trial vs. polymer-based drug-eluting stents.ISAR-SAFE: a randomized, double-blind, placebo-controlled trial of 6 vs. 12 months of clopidogrel therapy after drug-eluting stenting.Comparison of vascular closure devices vs manual compression after femoral artery puncture: the ISAR-CLOSURE randomized clinical trial.Rationale and design of a randomised clinical trial comparing vascular closure device and manual compression to achieve haemostasis after diagnostic coronary angiography: the Instrumental Sealing of ARterial puncture site - CLOSURE device versus manEuropean expert consensus on rotational atherectomy.Pathological aspects of bioresorbable stent implantation.Polymer-free sirolimus- and probucol-eluting versus new generation zotarolimus-eluting stents in coronary artery disease: the Intracoronary Stenting and Angiographic Results: Test Efficacy of Sirolimus- and Probucol-Eluting versus Zotarolimus-elutinNeoatherosclerosis: overview of histopathologic findings and implications for intravascular imaging assessment.Report of a European Society of Cardiology-European Association of Percutaneous Cardiovascular Interventions task force on the evaluation of coronary stents in Europe: executive summary.Rationale and design of the Prospective LongitudinAl Trial of FFRCT: Outcome and Resource IMpacts study.Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: a meta-analysis of randomised controlled trials.Optical Coherence Tomography Findings in Patients With Coronary Stent Thrombosis: A Report of the PRESTIGE Consortium (Prevention of Late Stent Thrombosis by an Interdisciplinary Global European Effort).Temporal Trends in Strut-Level Optical Coherence Tomography Evaluation of Coronary Stent Coverage: A Systematic Review and Meta-Analysis.Reduced duration of dual antiplatelet therapy using an improved drug-eluting stent for percutaneous coronary intervention of the left main artery in a real-world, all-comer population: Rationale and study design of the prospective randomized multiceDrug coated balloon angioplasty in the treatment of peripheral artery disease.Appraising the safety and efficacy profile of left atrial appendage closure in 2016 and the future clinical perspectives. Results of the EAPCI LAAC survey.Peer review at EuroIntervention - a rough guide and an expression of thanks.Association of increased CD8+ and persisting C-reactive protein levels with restenosis in HIV patients after coronary stenting.Comparison of the Absorbable Polymer Sirolimus-Eluting Stent (MiStent) to the Durable Polymer Everolimus-Eluting Stent (Xience) (from the DESSOLVE I/II and ISAR-TEST-4 Studies).Impact of bivalirudin on post-procedural epicardial blood flow, risk of stent thrombosis and mortality after percutaneous coronary intervention.Increased bleeding risk during percutaneous coronary interventions by arterial hypertension.Long-Term Efficacy and Safety of Paclitaxel-Eluting Balloon for the Treatment of Drug-Eluting Stent Restenosis: 3-Year Results of a Randomized Controlled Trial.Impact of inhospital stent thrombosis and cerebrovascular accidents on long-term prognosis after percutaneous coronary intervention.Bioresorbable vascular scaffolds in patients with acute myocardial infarction: a new step forward to optimized reperfusion?Peak cardiac troponin-T level, scintigraphic myocardial infarct size and one-year prognosis in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction.Platelet response to clopidogrel and restenosis in patients treated predominantly with drug-eluting stents.2-year clinical and angiographic outcomes from a randomized trial of polymer-free dual drug-eluting stents versus polymer-based Cypher and Endeavor [corrected] drug-eluting stents.Randomized trial of paclitaxel- versus sirolimus-eluting stents for treatment of coronary restenosis in sirolimus-eluting stents: the ISAR-DESIRE 2 (Intracoronary Stenting and Angiographic Results: Drug Eluting Stents for In-Stent Restenosis 2) stud
P50
Q30811584-8D1D22FB-0D18-41E1-BBB1-C7F113182441Q33801839-E74B75AD-D1D2-43E8-977E-ECBE5CB36B7AQ34002205-C5C3B94C-7053-4756-89BD-59E36C598BE0Q34476700-330D6F3D-87EB-4700-B89D-F7D7D6B5B30BQ34491530-A19D24D0-A3D0-4790-A4F5-7478E997D511Q35762839-43BD3B5F-D00E-46EA-AE77-4DFB9EEF8C33Q35894194-14A64E50-831C-4D2F-98B5-DCCA3341F757Q36154232-13F1D9ED-7332-4859-9870-2D561EFFA9A2Q36915078-A445D05A-FDDA-44BC-99E6-B217735E21F4Q38106541-E9CD96F3-9DFF-43EE-A304-CF3ABD18B3EDQ38196233-5B863B90-B708-4414-A2F1-6806E83C66DAQ38379261-AD5B1FE2-B3A7-4859-909F-4518C553209CQ38383496-EADD57FA-09C9-4924-BFC1-CF88DCA9F455Q38417372-E776A360-DA3F-4F59-A1B0-C49C44EE9862Q38420911-B00BC927-33A7-429C-98F0-114D402875B6Q38428012-25DF595B-85C9-4CBB-A229-2F29BF4C2797Q38486162-EACD9CD3-938D-4326-B38B-716837053A3CQ38486739-F1D1A857-F94A-43B4-BC76-BB8FA59BF05AQ38487695-BB767D38-E749-4913-A0CB-1425C00B5C83Q38494528-3FFEA782-1A44-4D21-9014-96EA80999129Q38526979-6453A943-0374-481D-BE74-26D66CF1051FQ38589186-B4638891-28CC-4E1D-9547-79DFDC1283E4Q38644678-1DF990D5-9010-4B61-A195-0BEE53D73B70Q38673193-2A8854E5-2D4B-430E-B0B2-E1BF7B7C5B0EQ38680749-F9D8142C-66A3-4106-9F8C-D7AAD3F6F31AQ38813973-5EC7324B-612F-46FA-BCB2-5858D287709DQ38827478-29B56760-894B-463E-905C-B50C4906DC93Q38867825-1398397C-C37C-4DEE-A2F9-282E61658D6DQ39014445-F462DBC2-1ACA-4D67-B207-2326F5E5E1CEQ39987031-1BACDA97-722D-4AA7-8652-8EF094B6891DQ40112459-8BA9177F-78D3-49D4-967A-E98A4DD10AA0Q40916892-FEE9CC99-BFBC-4078-A907-57D0476D63F1Q41156770-7CE0034A-9826-4575-8079-8A57A1ED7597Q41721224-F46EFB5B-0115-44F7-AF5B-EADC65C71A7BQ41744521-6D0A00D5-111A-439C-9FC1-2FE6390A3BB8Q42079506-D244C7A0-7A98-445E-B07F-642C39BCF4B2Q42844495-3EF5D46D-E71C-4B6C-863A-DBC59CBC82DEQ42943890-71F12B0C-CD08-4203-9375-ADB4042085BAQ43086787-C3DEE3F5-2C6B-4C2A-AA18-ABF20DE6DA13Q43131138-5F7259C0-283B-45F9-805B-302037EDF2D5
P50
description
researcher ORCID ID = 0000-0001-5224-6393
@en
wetenschapper
@nl
name
Robert A Byrne
@ast
Robert A Byrne
@en
Robert A Byrne
@es
Robert A Byrne
@nl
type
label
Robert A Byrne
@ast
Robert A Byrne
@en
Robert A Byrne
@es
Robert A Byrne
@nl
prefLabel
Robert A Byrne
@ast
Robert A Byrne
@en
Robert A Byrne
@es
Robert A Byrne
@nl
P1153
55941715200
P31
P496
0000-0001-5224-6393